42.03

18.33% 6.51

After Hours: 42.90 0.87 +2.07%

First Tracks Biotherapeutics Inc (TRAX)

Overview News Price History Discussions Forecast

First Tracks Biotherapeutics Inc stock is traded at $42.03, with a volume of 2.59M. It is up +18.33% in the last 24 hours and up +162.20% over the past month. First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.

Previous Close:

$35.52

Open:

$43.37

24h Volume:

2.59M

Relative Volume:

3.72

Market Cap:

$1.47B

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+14.00%

1M Performance:

+162.20%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$39.60

$46.45

1-Week Range:

$34.72

$46.45

52-Week Range:

$14.72

$46.45

First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile

Name

First Tracks Biotherapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (599)

Phone

212-373-3000

Address

10770 WATERIDGE CIRCLE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

TRAX's Discussions on Twitter

Compare TRAX vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TRAX First Tracks Biotherapeutics Inc	42.03	1.24B	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	479.00	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	667.17	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	888.82	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	188.07	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	278.40	36.28B	4.29B	577.22M	641.34M	4.2086

First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Initiated	Leerink Partners	Outperform
Apr-24-26	Initiated	Wedbush	Outperform
Apr-23-26	Initiated	JP Morgan	Overweight
Apr-22-26	Initiated	Barclays	Overweight
Apr-21-26	Initiated	UBS	Buy

First Tracks Biotherapeutics Inc Stock (TRAX) Latest News

02:04 AM

First Tracks Biotherapeutics: Buy Rating Reaffirmed with Unchanged $44 Price Target on ANB033 CD122-Targeting Upside and Acquisition Potential - TipRanks

02:04 AM

12:52 PM

After Forte acquisition, H.C. Wainwright says First Tracks could be target - TipRanks

12:52 PM

12:37 PM

TRAX Stock Volatile As Traders Focus On Cash And Momentum - StocksToTrade

12:37 PM

10:30 AM

Wedbush Adjusts First Tracks Biotherapeutics Price Target to $60 From $30, Maintains Outperform Rating - marketscreener.com

10:30 AM

Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill

10:30 AM

08:30 AM

These stocks that are showing activity before the opening bell on Monday. - ChartMill

08:30 AM

08:05 AM

First Tracks Biotherapeutics Ord Shs (TRAX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 23, 2026

Jul 21, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 21, 2026

Jul 20, 2026

Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $54 - Moomoo

Jul 20, 2026

Jul 18, 2026

TRAX Stock Hits All-Time High — What's Driving The Super Rally? - Stocktwits

Jul 18, 2026

Jul 17, 2026

First Tracks Biotherapeutics (TRAX) Stock Forum and Discussion - Moomoo

Jul 17, 2026

Jul 16, 2026